
Sign up to save your podcasts
Or


Ruvim Izĭckson discusses the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine together with a third dose of the Moderna COVID-19 vaccine in adults aged 65 years and older.
Read the full article:
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 year
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
11 ratings
Ruvim Izĭckson discusses the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine together with a third dose of the Moderna COVID-19 vaccine in adults aged 65 years and older.
Read the full article:
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 year
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

320 Listeners

497 Listeners

2 Listeners

37 Listeners

366 Listeners

22 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

16,083 Listeners

1 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

909 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners